Free Trial

Crinetics Pharmaceuticals (CRNX) Competitors

Crinetics Pharmaceuticals logo
$34.65 +1.35 (+4.05%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$35.58 +0.93 (+2.67%)
As of 09/3/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRNX vs. QGEN, MRNA, BBIO, ELAN, VRNA, ROIV, GRFS, RVMD, RYTM, and LEGN

Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

Crinetics Pharmaceuticals vs. Its Competitors

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Crinetics Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Qiagen has a net margin of 18.30% compared to Crinetics Pharmaceuticals' net margin of 0.00%. Qiagen's return on equity of 14.77% beat Crinetics Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Crinetics PharmaceuticalsN/A -32.28% -29.45%
Qiagen 18.30%14.77%8.87%

Crinetics Pharmaceuticals presently has a consensus price target of $68.86, suggesting a potential upside of 98.72%. Qiagen has a consensus price target of $49.69, suggesting a potential upside of 6.45%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Qiagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crinetics Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78
Qiagen
0 Sell rating(s)
8 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.27

Qiagen has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$1.39M2,344.25-$298.41M-$4.11-8.43
Qiagen$2.04B5.09$83.59M$1.6927.62

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Qiagen had 12 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 23 mentions for Qiagen and 11 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.52 beat Qiagen's score of 0.93 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Crinetics Pharmaceuticals
10 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Qiagen
10 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Qiagen beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Crinetics Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRNX vs. The Competition

MetricCrinetics PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.14B$2.51B$5.77B$9.76B
Dividend YieldN/A48.51%6.66%4.49%
P/E Ratio-8.4322.6482.3726.60
Price / Sales2,344.25709.47525.54161.29
Price / CashN/A26.3325.7028.92
Price / Book2.796.7910.646.56
Net Income-$298.41M$32.94M$3.28B$266.04M
7 Day Performance13.05%0.80%0.10%-0.89%
1 Month Performance22.79%6.13%8.91%4.34%
1 Year Performance-34.38%-0.23%48.38%24.06%

Crinetics Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRNX
Crinetics Pharmaceuticals
3.7944 of 5 stars
$34.65
+4.1%
$68.86
+98.7%
-33.4%$3.14B$1.39M-8.43210News Coverage
Positive News
QGEN
QIAGEN
4.2572 of 5 stars
$48.92
-1.6%
$49.69
+1.6%
+8.4%$11.06B$1.98B28.905,765
MRNA
Moderna
4.5519 of 5 stars
$25.35
-6.5%
$42.88
+69.2%
-67.0%$10.55B$3.24B-3.375,800
BBIO
BridgeBio Pharma
4.1579 of 5 stars
$47.29
-3.6%
$61.35
+29.7%
+80.4%$9.38B$221.90M-11.56400Positive News
Analyst Forecast
ELAN
Elanco Animal Health
3.0978 of 5 stars
$17.80
-0.6%
$17.33
-2.6%
+14.4%$8.90B$4.48B20.709,000Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.386 of 5 stars
$105.62
+0.1%
$109.00
+3.2%
+290.2%$8.64B$221.67M-106.6930News Coverage
Positive News
ROIV
Roivant Sciences
3.1411 of 5 stars
$11.64
-2.3%
$16.50
+41.8%
+7.0%$8.14B$29.05M-16.63860News Coverage
Positive News
Analyst Forecast
GRFS
Grifols
3.9212 of 5 stars
$9.82
-3.3%
$10.30
+4.9%
+2.2%$6.99B$7.81B8.3923,822Positive News
RVMD
Revolution Medicines
4.4711 of 5 stars
$35.67
-3.6%
$69.92
+96.0%
-4.3%$6.92BN/A-7.93250Positive News
RYTM
Rhythm Pharmaceuticals
3.3078 of 5 stars
$99.20
-3.9%
$101.57
+2.4%
+121.3%$6.86B$130.13M-32.96140News Coverage
Positive News
LEGN
Legend Biotech
3.5173 of 5 stars
$34.60
-2.7%
$73.00
+111.0%
-37.3%$6.53B$627.24M-39.322,609

Related Companies and Tools


This page (NASDAQ:CRNX) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners